|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues显示文摘Hepatocellular carcinoma(HCC) is a major health problem worldwide, representing one of the leading causes of death. Chronic hepatitis B virus(HBV) infection(CHB) is the most important etiologic factor of this tumor, accounting for the development of more than50% of the cases in the world. Primary prevention ofHCC is possible by hepatitis B vaccination conferring protection from HBV infection. However, according to the World Health Organization Hepatitis B Fact sheet N° 204(update of July 2014) globally there exists a large pool of > 240 million people chronically infected with HBV who are at risk for development of HCC. These individuals represent a target population for secondary prevention both of cirrhosis and of HCC. Since ongoing HBV replication in CHB is linked with the progression of the underlying liver disease to cirrhosis as well as with the development of HCC, effective antiviral treatment in CHB has also been evaluated in terms of secondary prevention of HCC. Currently, most patients with active CHB are subjected to long term treatment with the first line nucleos(t)ide analogues entecavir and tenofovir. These compounds are of high antiviral potency and have a high barrier to HBV resistance compared to lamivudine, adefovir dipivoxil and even telbivudine. Many studies have shown that patients under antiviral treatment, especially those in virological remission, develop less frequently HCC compared to the untreated ones. However, the risk for development of HCC cannot be eliminated. Therefore, surveillance for the development of HCC of patients with chronic hepatitis B must be lifelong or until a time in the future when new treatments will be able to completely eradicate HBV from the liver particularly in the early stages of CHB infection. In this context, the aim of this review is to outline the magnitude of the risk for development of HCC among patients with CHB, in the various phases of the infection and in relation to virus, host and environmental factors as evaluated in the world literature. Moreover, the benefits of antiviral treatment of CHB with nucleos/tide analogs, which have changed the natural history of the disease and have reduced but not eliminated the risk of HCC are also reviewed. | Irene Rapti Stephanos Hadziyannis | 2015 | World Journal of Hepatology2015，7，8： | 20 |
| 2 | Interferon-a plus lamivudine vslamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B显示文摘AIM: To investigate the efficacy of combination treatment of IFN-α and lamivudine compared to lamivudine monotherapy, after 24 mo of administration in HBeAg-negative hepatitis B patients.METHODS: Fifty consecutive patients were randomly assigned to receive IFN-α-2b (5 MU thrice per week, n = 24) plus lamivudine (100 mg daily) or lamivudine only (n = 26) for 24 mo. Patients were followed up for further 6 mo. The primary outcome was the proportion with sustained virological response (undetectable serum HBV DNA concentrations) and or sustained biochemical response (transaminase levels within normal range) at 30 mo (6 mo after the end of therapy). Secondary end-points were timed from initial virological (biochemical) response to VBR (BBR, respectively) and the emergence of YMDD mutants across the two arms.RESULTS: Five of twenty-four (21%) patients in the combination arm vs 3/26 (12%) in the lamivudine arm had sustained response (i.e., normal serum transaminase levels and undetectable HBV DNA by PCR assay) 6 mo after treatment discontinuation. A reduction in the emergence of YMDD mutants and in the development of virological breakthroughs was observed in patients receiving combination treatment (10% vs46%, P= 0.01 and 14% vs46%, P= 0.03,respectively).Time from initial virologic response to virologic breakthrough (VBR) was greater among initial responders receiving combination treatment compared to those receiving lamivudine (22.9 mo vs 15.9 mo, respectively; P = 0.005).CONCLUSION: Our results demonstrate that IFN-α plus lamivudine combination therapy does not increase the sustained response, compared to lamivudine. However,combination therapy reduces the likelihood of VBR due to YMDD mutants and prolongs the time period until the breakthrough development. | Michalis Economou Spilios Manolakopoulos Thomas A Trikalinos Spyros Filis Sotiris Bethanis Dimitrios Tzourmakliotis Alec Avgerinos Sotiris Raptis Epameinondas V Tsianos | 2005 | World Journal of Gastroenterology2005，11，37： | 6 |
| 3 | Role of advanced magnetic resonance imaging in the assessment of malignancies of the mediastinum显示文摘In the new era of functional magnetic resonance imaging(MRI), the utility of chest MRI is increasing exponentially due to several advances, including absence of ionizing radiation, excellent tissue contrast and high capability for lesion characterization and treatment monitoring. The application of several of these diagnostic weapons in a multiparametric fashion enables to better characterize thymic epithelial tumors and other mediastinal tumoral lesions, accurate assessment of the invasion of adjacent structures and detection of pathologic lymph nodes and metastasis. Also, 'do not touch lesions' could be identified with the associated impact in the management of those patients. One of the hotspots of the multiparametric chest MR is its ability to detect with acuity early response to treatment in patients with mediastinal malignant neoplasms. This has been related with higher rates of overall survival and progression free survival.Therefore, in this review we will analyze the current functional imaging techniques available(18 F-Fluorodeoxiglucose positron emission tomography/computed tomography, diffusion-weighted imaging, dynamic contrast-enhanced MRI, diffusion tensor imaging and MR spectroscopy) for the evaluation of mediastinal lesions, with a focus in their correct acquisition and post-processing. Also, to review the clinical applications of these techniques in the diagnostic approach of benign and malignant conditions of the mediastinum. | Jordi Broncano Ana María Alvarado-Benavides Sanjeev Bhalla Antonio álvarez-Kindelan Constantine A Raptis Antonio Luna | 2019 | World Journal of Radiology2019，11，3： | 4 |
| 4 | Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir显示文摘 | Stephanos J. Hadziyannis Vassilios Sevastianos Irene Rapti Dimitrios Vassilopoulos Emilia Hadziyannis | 2012 | Gastroenterology2012，，3： | 2 |
| 5 | 阿利吉仑对2型糖尿病合并高血压患者循环内皮祖细胞和血管功能的影响显示文摘该研究旨在探讨阿利吉仑对2型糖尿病合并高血压患者循环内皮祖细胞(endothelial progenitor cells,EPC)和血管功能的影响。方法:研究纳入血糖控制稳定、首次诊断为轻度原发性高血压〉50岁的2型糖尿病患者。在A阶段(n=20),患者接受150-300mg/d阿利吉仑治疗3月。 | Raptis AE Markakis KP Mazioti MC Ikonomidis I Maratou EP Vlahakos DV Kotsifaki EE Voumvourakis AN Tsiro- gianni AG Lambadiari VA Lekakis JP Raptis SA Dimitria- dis GD 练桂丽 叶鹏 | 2015 | 中华高血压杂志2015，23，7： | 2 |
| 6 | Novel and Simple Preoperative Score Predicting Complications After Liver Resection in Noncirrhotic Patients显示文摘 | Stefan Breitenstein Michelle L. DeOliveira Dimitri A. Raptis Ksenija Slankamenac Patryk Kambakamba Jakob Nerl Pierre-Alain Clavien | 2010 | Annals of Surgery2010，，5： | 2 |
| 7 | Pathogenesis of diabetic nephropathy显示文摘 | Raptis AE Viberti G | 2001 | Exp Clin Endocr Diab2001，109，2： | 1 |
| 8 | Component mining:A process and its pattern language显示文摘 | Spinellis D Raptis K | 2000 | Information and Software Technology2000，42，9： | 1 |
| 9 | Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in pa- tients with small-cell lung cancer: A Phase Ⅲ study 显示文摘 | Dimitroulis J Rapti A Stathopoulos GP | 2008 | Oncol Rep2008，20，4： | 1 |
| 10 | Optical behavior of current ceramic systems显示文摘 | Raptis NV Michalakis KX Hirayama H | | 0，，01： | 1 |
| 11 | Identification of mammaglobin as a novel serum marker for breast cancer 显示文摘 | Bemstein JL Godbold JH Raptis G | 2005 | Clin Cancer Res2005，11，18： | 1 |
| 12 | somatostatin and octreotide in the management of acute variceal hemorrhage 显示文摘 | Avgerinos A Armonis A Raptis S | 1995 | Hepatagastroenterology1995，42，2： | 1 |
| 13 | Dipeptidyl pepti- daze I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis 显示文摘 | Adkison AM Raptis SZ Kelley DG | 2002 | J Clin In- vest2002，109，3： | 1 |
| 14 | Parametric and modulational instabilities of the discrete nonlinear Schr? dinger equation显示文摘 | Rapti Z Kevrekidis P G Smerzi A | 2004 | J Phys B2004，37，： | 1 |
| 15 | Insulin action in hyperthyroidism: a focus on muscle and adipose tissue显示文摘 | Mitrou P Raptis S A Dimitriadis G | 2010 | Endocr Rev2010，31，5： | 1 |
| 16 | Electrochemical promotion of conventional and bipolar reactor configurations for NO reduction显示文摘 | Pliangos C Raptis C Bolzonella I | 2002 | Ionics2002，8，56： | 1 |
| 17 | Autonomic rectal dysfunctionin patients with multiple sclerosis and bowel symptoms is secondary to spinal cord disease 显示文摘 | Preziosi G Raptis DA Raebum A | 2014 | Dis Colon Rectum2014，57，4： | 1 |
| 18 | Component Mining: a process and its pattern language显示文摘 | Spinellis D Raptis K | 2000 | Information and Software Technology2000，，42： | 1 |
| 19 | Efficacy of the novel very long-acting β2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma 显示文摘 | Nandeuil A Kottakis I Raptis H | 2006 | Eur Respir J2006，28，50： | 1 |
| 20 | Adrenaloma: A Call for More Aggressive Management显示文摘 | Linos D A Stylopoulos N Raptis S A | 1996 | World J Surg1996，20，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员